Wall Street Analysts See a 64.09 percent Upside in Monte Rosa Therapeutics Can the Stock Really Move This High?
| IMAB Stock | USD 1.06 0.01 0.95% |
About 51% of I Mab's investors are presently thinking to get in. The analysis of the overall investor sentiment regarding I Mab suggests that some traders are interested. The current market sentiment, together with I Mab's historical and current headlines, can help investors time the market. In addition, many technical investors use I Mab stock news signals to limit their universe of possible portfolio assets.
IMAB |
The mean of analysts price targets for Monte Rosa Therapeutics points to a 64.1 percent upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Read at zacks.com
 |
I Mab Investor Sentiment by Other News Outlets
Investor sentiment, mood or attitude towards I Mab can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
I Mab Fundamental Analysis
We analyze I Mab's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of I Mab using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of I Mab based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Probability Of Bankruptcy
Probability Of Bankruptcy Comparative Analysis
I Mab is currently under evaluation in probability of bankruptcy category among its peers. Probability Of Bankruptcy is a relative measure of the likelihood of financial distress. For stocks, the Probability Of Bankruptcy is the normalized value of Z-Score. For funds and ETFs, it is derived from a multi-factor model developed by Macroaxis. The score is used to predict the probability of a firm or a fund experiencing financial distress within the next 24 months. Unlike Z-Score, Probability Of Bankruptcy is the value between 0 and 100, indicating the firm's actual probability it will be financially distressed in the next 2 fiscal years.
I Mab Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with I Mab stock to make a market-neutral strategy. Peer analysis of I Mab could also be used in its relative valuation, which is a method of valuing I Mab by comparing valuation metrics with similar companies.
Peers
I Mab Related Equities
| NRIX | Nurix Therapeutics | 6.78 | ||||
| STTK | Shattuck Labs | 4.00 | ||||
| KYMR | Kymera Therapeutics | 3.21 | ||||
| DSGN | Design Therapeutics | 1.69 | ||||
| BPMC | Blueprint Medicines | 0.87 | ||||
| KRYS | Krystal Biotech | 0.73 | ||||
| RVMD | Revolution Medicines | 0.53 | ||||
| LYEL | Lyell Immunopharma | 0.54 | ||||
| FHTX | Foghorn Therapeutics | 0.63 | ||||
| ERAS | Erasca | 0.67 | ||||
| IMVT | Immunovant | 0.79 | ||||
| APLS | Apellis Pharmaceuticals | 1.09 | ||||
| CGEM | Cullinan Oncology | 1.18 | ||||
| AKRO | Akero Therapeutics | 1.54 | ||||
| ASND | Ascendis Pharma | 2.08 | ||||
| GLUE | Monte Rosa | 7.45 | ||||
| BGNE | BeiGene | 9.69 |
Complementary Tools for IMAB Stock analysis
When running I Mab's price analysis, check to measure I Mab's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy I Mab is operating at the current time. Most of I Mab's value examination focuses on studying past and present price action to predict the probability of I Mab's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move I Mab's price. Additionally, you may evaluate how the addition of I Mab to your portfolios can decrease your overall portfolio volatility.
| Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital | |
| Portfolio Diagnostics Use generated alerts and portfolio events aggregator to diagnose current holdings | |
| Money Flow Index Determine momentum by analyzing Money Flow Index and other technical indicators | |
| Competition Analyzer Analyze and compare many basic indicators for a group of related or unrelated entities |